Cubist Pharmaceuticals Inc., Cambridge, Mass., and Bristol-Myers Squibb Co., New York, have announced the extension of the three-year collaborative research and license agreement the two entered into in June of 1996. The collaboration focused on treatment of infectious diseases. "The collaboration has worked well, and there is still more work to be done," says Scott M. Rocklage, Ph.D., president and CEO of Cubist. "We are pleased by Bristol-Myers Squibb's commitment to continue the collaboration and to work toward advancing the program to the next level." Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development, and commercialization of antimicrobial drugs to combat serious and life-threatening bacteria and fungal infections.